Castle Biosciences Inc
CSTL Nasdaq· Services-Medical Laboratories
Last close · Oct 26, 2026
$33.30
KIRA · Stoqly’s AI analyst, in plain words
- Castle Biosciences Inc had $344M of revenue in fiscal 2025, up 3.7% on the year before. Over five years, revenue changed +40.6% a year on average.
- Its operating margin was −12.4%, down 15.0 pts: of every 100 in sales, about −12 is left after running the business.
- Castle Biosciences Inc lost $24.2M in fiscal 2025.
- Free cash flow was $28.3M in fiscal 2025, 8.2% of revenue.
- Castle Biosciences Inc has $289M more cash than debt.
Market cap
$1.0B
P/E
—
Revenue
$344M
Net income
−$24.2M
Free cash flow
$28.3M
Operating margin
−12.4%
Castle Biosciences Inc in 30 seconds · fiscal 2025
Are sales growing?
+3.7%
Only a little. Sales grew 3.7% last year.
Does it make a profit?
−7.0%
No. It lost money last year.
Does profit turn into cash?
8.2%
Partly. 8.2% of sales ends up as free cash.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Castle Biosciences Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- CASTLE BIOSCIENCES INC
- CIK
- 0001447362
Castle Biosciences Inc · CSTL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $94.1M | $137M | $220M | $332M | $344M |
| Revenue growth | 50.2% | 45.7% | 60.4% | 51.1% | 3.7% |
| Gross margin | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| Operating margin | −42.6% | −53.2% | −30.9% | 2.6% | −12.4% |
| Net income | −$31.3M | −$67.1M | −$57.5M | $18.2M | −$24.2M |
| Net margin | −33.3% | −49.0% | −26.1% | 5.5% | −7.0% |
| Diluted EPS | −$1.24 | −$2.58 | −$2.14 | $0.62 | −$0.83 |
| Cash | |||||
| Cash from operations | −$19.0M | −$41.7M | −$5.6M | $64.9M | $64.3M |
| Capital expenditure | $3.5M | $5.6M | $13.6M | $28.3M | $36.0M |
| Free cash flow | −$22.5M | −$47.3M | −$19.2M | $36.5M | $28.3M |
| FCF margin | −23.9% | −34.5% | −8.8% | 11.0% | 8.2% |
| Share count change | 32.8% | 3.6% | 2.9% | 9.2% | −0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $330M | $259M | $243M | $293M | $300M |
| Debt incl. finance leases | — | — | $0.1M | $10.4M | $10.5M |
| Shareholders' equity | $412M | $399M | $391M | $456M | $471M |
| Net debt / EBITDA | — | — | — | −11.5x | — |
| Current ratio | 14.2x | 8.1x | 6.2x | 7.3x | 5.3x |
| Interest coverage | −40,079.0x | −4,285.6x | −6,179.7x | 15.0x | −497.8x |
| Returns and quality | |||||
| Return on capital | — | — | −36.2% | 4.0% | −18.6% |
| Return on equity | −7.6% | −16.6% | −14.5% | 4.3% | −5.2% |
| Return on tangible equity | −9.7% | −24.6% | −21.0% | 5.2% | −6.5% |
| Piotroski F-score | 2 | 2 | 4 | 7 | 4 |
| Altman Z'' | 11.9 | 10.2 | 7.6 | 9.1 | 6.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$19.2M
5 insiders
Of sales under plans
84%
$16.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Castle Biosciences Inc · CSTL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $33.30 a share, the company is worth $1.0B.
Source: SEC EDGAR XBRL filings (CIK 0001447362). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.